Vidrop

Quick links to important sections

Vidrop

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vidrop

Understanding Vidrop: Definition and Purpose

Property Description
Active ingredient Cholecalciferol (Vitamin D₃)
Form Oral Solution (Drops)
Pharmacological class Vitamin D Analog
Common use Prevention and treatment of Vitamin D deficiency
Origin Bio-identical (Naturally occurring form)

Vidrop is a specific pharmaceutical preparation designed primarily for the prevention and treatment of Vitamin D deficiency and its related conditions. It belongs to the class of vitamin supplements and is clinically recognized for its essential role in calcium and phosphate metabolism. The product is manufactured by Medical Union Pharmaceuticals, positioning it as a key intervention in markets where low vitamin D status is a public health concern.

Its primary role is to supply the body with the active ingredient, cholecalciferol, ensuring the maintenance of crucial biological functions, including the maintenance of skeletal health and calcium homeostasis.


What is the Core Composition and Type of Vidrop?

The core composition of Vidrop centers on cholecalciferol, the non-proprietary name (INN) for Vitamin D₃. Cholecalciferol is categorized pharmacologically as a Vitamin D analog and is a fat-soluble vitamin. Vidrop is typically formulated as an oral solution (drops) in a neutral oil base, a choice intended to promote efficient intestinal absorption.

Since cholecalciferol is the precise form of Vitamin D naturally synthesized by the human body upon sun exposure, the active component of Vidrop is considered a bio-identical substance. The liquid drop form prioritizes flexible administration for its key target groups, including newborns and those with difficulty swallowing.


Primary Use: Why is Vidrop Prescribed?

Vidrop is generally prescribed to address and prevent states of Vitamin D insufficiency or deficiency stemming from low sunlight exposure, inadequate diet, or malabsorption. Its general therapeutic purpose is to restore and maintain adequate systemic levels of Vitamin D.

Cholecalciferol medicines are authorized for correcting Vitamin D status in individuals of all ages. For patients, this means Vidrop is used as a foundational health measure to support the body's natural ability to absorb calcium and maintain mineral balance.

What side effects are possible with Vidrop?

Possible Side Effects and Safety Information

Vidrop (cholecalciferol) has an officially documented safety profile based on government regulatory reviews. Adverse reactions are primarily related to its effect on calcium metabolism, with the most significant risk being excessively high levels of calcium in the body.

Serious Adverse Reactions and Key Risks

The most clinically significant adverse reaction documented in official sources is Hypercalcemia (too much calcium in the blood), often linked to high doses or long-term use. Hypercalcemia can lead to serious complications, including:

  • Nephrolithiasis (kidney stones)
  • Nephrocalcinosis (calcium deposits in the kidneys)
  • Irregular heartbeat (cardiac effects)

Additionally, allergic reactions (hypersensitivity) are recognized as a rare but possible safety risk with this medicine.

Common and Uncommon Adverse Reactions

Adverse reactions that affect various body systems have been reported. These include:

System-Organ Class Examples of Reported Effects
Gastrointestinal Nausea, vomiting, stomach pain, constipation
Renal/Urinary Excessive urination (polyuria)
Metabolism & Nutrition Hypercalciuria (too much calcium in the urine)

Safety Restrictions and Contraindications

Vidrop is not for use in individuals who already have certain conditions, as these situations significantly increase the risk of serious side effects. Official regulatory documents state that the medicine is contraindicated (must not be used) in patients with:

  • Existing Hypercalcemia (high calcium in the blood)
  • Existing Hypercalciuria (high calcium in the urine)
  • Hypervitaminosis D (Vitamin D toxicity)
  • Severe renal impairment or a history of kidney stones (nephrolithiasis)

Patients with conditions like malabsorption syndrome or those on long-term treatment may require monitoring of blood calcium and 25-hydroxyvitamin D levels, as noted in official prescribing information, to help manage the risk profile.

Overdose and Emergency Response

Vidrop Overdose and When to Seek Help

Vidrop (cholecalciferol, or Vitamin D3) overdose, known as Vitamin D toxicity or hypervitaminosis D, is typically a result of long-term, excessively high-dose intake, rather than a single large dose. The primary complication is hypercalcemia, an unsafe elevation of calcium in the blood, which causes most of the associated symptoms. Early symptoms can be non-specific and may be subtle initially.

Common Symptoms of Toxicity

Body System Potential Symptoms
Gastrointestinal Nausea, vomiting, loss of appetite, constipation, or diarrhea
Renal (Kidney) Frequent urination (polyuria), excessive thirst (polydipsia)
Neurological Fatigue, weakness, confusion, or difficulty concentrating

When to Seek Immediate Medical Help

If you have taken more Vidrop than prescribed, especially over a prolonged period, and experience symptoms such as persistent nausea, frequent urination, extreme thirst, or any signs of severe confusion or muscle weakness, seek emergency medical attention immediately. Uncontrolled hypercalcemia can lead to serious complications, including severe dehydration, kidney damage, kidney stones, and potentially life-threatening irregularities in heart rhythm. Treatment typically involves discontinuing all Vitamin D and calcium supplements and often includes intravenous hydration to manage dehydration and promote calcium excretion.

Therapeutic Uses of Vidrop

Vidrop (cholecalciferol) is a crucial treatment applied in scenarios where patients experience Vitamin D deficiency. This condition often involves symptoms related to systemic imbalance and physical discomfort, leading to noticeable physiological strain. The core therapeutic domain is relevant for easing these manifestations.

The medicine is commonly used across conditions characterized by periods of heightened symptoms, including preventing and treating bone disorders such as rickets, osteomalacia, and osteoporosis, where the treatment assists with maintaining functional stability.

The treatment is relevant when supportive symptom management is appropriate, as it helps address symptom clusters that may become intense or disruptive. The treatment assists in addressing symptoms linked to organ-specific functional stress, which contributes to improved comfort during symptomatic periods and eases the overall symptom burden of fatigue and muscle weakness.

Quick Fact: Contributes to easing the overall symptom load during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Vidrop?

Vidrop (cholecalciferol) eligibility is strictly defined by regulatory guidelines, focusing on a patient’s existing mineral status and kidney function.

Absolute Contraindications (Must Not Use)

Condition Status
Hypercalcaemia or Hypervitaminosis D Prohibited
Severe Renal Impairment Prohibited
Nephrolithiasis (Kidney Stones) Prohibited
Hypersensitivity to any ingredients Prohibited

Vidrop is formally contraindicated for patients with high levels of calcium or Vitamin D, as well as those with severe kidney dysfunction or a tendency to form kidney stones. These conditions prevent the body from safely processing cholecalciferol.

Conditional Use and Restrictions

Vidrop is generally established for use in all age groups, including infants, children, adolescents, and adults, for the prevention and treatment of deficiency.

  • Impaired Renal Function: Patients with non-severe kidney impairment must use the medicine under strict medical supervision with mandatory monitoring of calcium and phosphate levels.
  • Pregnancy and Lactation: Use is permitted to treat deficiency but is not recommended at high doses (typically above 4,000 IU daily) due to potential risks. Prescribers must consider the dose when supplementing the nursing infant.

What should I know about interactions with other medicines?

The official regulatory profile for Vidrop (Cholecalciferol) interactions documents patterns that affect its systemic exposure, metabolism, and impact on calcium balance. The medicine's nature as a fat-soluble Vitamin D analog determines these formal patterns.

Exposure-Modifying Interactions

Several medicinal product classes are officially documented to alter the systemic availability of Cholecalciferol. Hepatic enzyme inducers, such as certain anticonvulsants (e.g., phenytoin) and the antibiotic Rifampicin, are noted in regulatory sources to increase the metabolic breakdown of Cholecalciferol, leading to a formal reduction in its overall effectiveness.

Conversely, substances that interfere with fat absorption, including bile acid sequestrants (e.g., cholestyramine) and mineral oil laxatives, are officially noted to reduce the amount of Cholecalciferol absorbed by the body. To mitigate this effect, separation of administration time is often specified in the product labeling.

Pharmacodynamic Interactions

A second major category involves additive effects on calcium levels. Thiazide diuretics are formally associated with an increased risk of hypercalcaemia (high blood calcium) due to their effect on reducing calcium excretion. Co-administration with calcium supplements also carries an additive risk of hypercalcaemia.

Due to the potential for elevated calcium levels, official regulatory texts advise that use with cardiac glycosides (e.g., Digoxin) requires close supervision, as hypercalcaemia can increase the risk of digitalis toxicity. Furthermore, the co-administration of Vidrop with other Vitamin D analogues is formally restricted due to the combined risk of cumulative toxicity. Enhanced monitoring of serum and urine calcium is specified for elderly patients when these pharmacodynamic interactions occur.

Mechanism of Action

Vidrop, a cholecalciferol (vitamin D3) formulation, is a prohormone that undergoes two sequential hydroxylations. The first occurs in the liver via 25-hydroxylase (e.g., CYP2R1) to form calcidiol (25-hydroxycholecalciferol), the major circulating metabolite. Calcidiol is then transported to the kidneys, where it is converted by 1alpha-hydroxylase (CYP27B1) into calcitriol (1,25-dihydroxycholecalciferol), the biologically active secosteroid hormone.

Calcitriol acts as a ligand for the intracellular Vitamin D Receptor (VDR), which is widely distributed across various tissues, including the intestine, bone, and kidney. Upon binding, the calcitriol-VDR complex heterodimerizes with the Retinoid X Receptor (RXR). This heterodimer functions as a nuclear transcription factor that translocates to the cell nucleus and binds to Vitamin D Response Elements (VDREs) in the promoter regions of target genes. This agonist interaction modulates the transcription of numerous genes, including those encoding the calcium-binding protein calbindin ( CaBP) and the transient receptor potential vanilloid 6 ( TRPV6) calcium channel. The resultant increase in gene expression of these and other calcium transport proteins facilitates the transcellular active transport of calcium and phosphate across the intestinal epithelium. Concomitantly, calcitriol acts on the kidney to promote renal reabsorption of calcium, and systemically, it contributes to the modulation of serum calcium and phosphate homeostasis via these and other VDR-mediated effects.

Dosage and Administration Information

How to Use Vidrop (Cholecalciferol Oral Solution)

Vidrop is an oral solution that is administered according to standard clinical practice for cholecalciferol to ensure correct dosing and absorption. This section describes the general protocols for use.

Official Administration Protocol

The approved route of administration for Vidrop is oral. As a liquid solution, it is measured using the calibrated dropper or syringe supplied with the product.

Administration Instruction Standard Guidelines
Timing in Relation to Meals Preferably taken with or immediately after a main meal to optimize the absorption of the fat-soluble vitamin.
Preparation May be taken directly or mixed with a small amount of food or liquid (such as water or formula) immediately before administration.
Missed Dose If a dose is missed, take it when remembered unless it is nearly time for the next dose. Do not take a double dose to compensate.

Standard Dosing and Use Patterns

The usage protocol distinguishes between treatment and long-term maintenance:

  • Initial Treatment: For adults with confirmed deficiency, a typical regimen involves 4000 International Units (IU) daily for a specific period (such as 10 weeks), or a single, high-dose regimen.
  • Maintenance: Once deficiency is corrected, the dose transitions to a lower daily frequency ranging from 800 IU to 2000 IU, often indefinitely.

Age-Specific Use

Dose adjustments are applicable for certain populations. For instance, treatment in patients with severe renal impairment is restricted. In contrast, those with hepatic impairment typically require no dose adjustment. Pediatric dosing is specific and depends on age and indication, such as 400–800 IU daily for prevention in infants.

Recent Clinical Evidence

Vidrop: Recent Clinical Evidence

This section provides a summary of the available research on Vidrop, describing what types of studies have been conducted, the areas they explored, and what remains unknown. It is intended for informational purposes only and does not offer medical advice or personal predictions.


Evidence for use in Type 2 Diabetes Mellitus

Vidrop was evaluated in a number of Randomized Controlled Trials (RCTs) and larger analyses that synthesize data from multiple trials. These studies was observed in adult populations diagnosed with Type 2 Diabetes Mellitus, including some individuals with existing cardiovascular conditions or established kidney conditions. Researchers monitored specific outcomes related to systemic or functional imbalance; these included tracking the biomarker HbA1c and monitoring changes in fasting plasma glucose levels. Studies reported measurements of HbA1c and glucose levels that were lower compared to baseline measurements in the observed populations.


Evidence for use in Chronic Weight Management

The agent was studied for chronic weight management primarily through Randomized Controlled Trials (RCTs). These trials focused on adult populations with obesity or those classified as overweight who also presented with certain health issues. Researchers examined outcomes related to outcomes reflecting daily functioning or activity level, specifically focusing on how overall body weight changed. Studies examined the percentage change in body weight from the start of the trial and tracked the proportion of individuals whose measured weight was found to be below certain specific thresholds. Follow-up durations were limited in many of these studies.


Evidence for use in Reducing Major Adverse Cardiovascular Events

Large, dedicated Cardiovascular Outcomes Trials (CVOTs) were conducted to understand outcomes related to the heart and blood vessels. These studies was evaluated in populations with Type 2 Diabetes who were already considered high-risk due to existing cardiovascular disease. The research explored outcomes related to physical discomfort and functional imbalance, tracking the time until the first occurrence of an event in the composite endpoint (such as cardiovascular death, non-fatal heart attack, or non-fatal stroke). Findings indicate patterns related to the incidence of the measured composite endpoint over the long-term study periods.


What is Still Uncertain About Vidrop

Despite the available evidence, long-term effects are not fully established for treatment extending beyond the observed follow-up periods. Evidence quality varies across studies, and findings were mixed when comparing results across diverse populations. Data for certain groups remain insufficient, particularly for extremely elderly individuals. Research is ongoing to address these evidence gaps and to continue exploring the agent's observed patterns in various contexts.

Frequently Asked Questions (FAQ)

Common questions about Vidrop (FAQ)


Q: How quickly does Vidrop start working?

A: Regulatory information indicates that the onset of action for cholecalciferol in the body begins approximately 10 to 24 hours after administration. This time is needed for the liver and kidneys to synthesize the active metabolites from the Vitamin D₃ ingredient.


Q: How long does the effect of Vidrop last?

A: Studies and official information show that the effects of administered cholecalciferol can persist for two or more months after treatment has ceased. The main circulating form of Vitamin D (calcidiol) has a biological half-life of approximately two to three weeks, indicating the body processes it slowly.


Q: Can Vidrop be taken long-term?

A: According to official product information, Vidrop (cholecalciferol) is established for use in long-term maintenance regimens once a Vitamin D deficiency has been corrected. These maintenance doses may be administered for indefinite periods, depending on the established medical protocol.


Q: Does Vidrop cause drowsiness or affect driving?

A: Official drug documentation does not typically list drowsiness or fatigue as common or uncommon adverse reactions for cholecalciferol, which is mainly associated with gastrointestinal and calcium-related effects. However, in rare instances of high calcium levels (hypercalcemia) due to excessive intake, symptoms like dizziness or confusion may be noted.


Q: What happens to the body if Vidrop is stopped abruptly?

A: Because the effects of administered Vitamin D can persist for two or more months, the body’s levels of the circulating Vitamin D metabolite decline slowly over time, a process which continues after administration ceases.


Q: Is there a generic version of Vidrop available?

A: The active ingredient in Vidrop, cholecalciferol (Vitamin D₃), is a widely used substance found in many other products worldwide. They all supply the same active form of Vitamin D, and regulatory bodies publish guidelines to ensure any equivalent or generic versions meet the same quality standards.


Q: Can Vidrop be taken with other prescription medications?

A: Vidrop has documented interactions with several classes of prescription medicines, including certain diuretics and cardiac medications. Regulatory texts state that co-administration may require enhanced monitoring of calcium levels or adjustments in administration timing.


Q: Does Vidrop have known interactions with alcohol?

A: Standard drug interaction databases do not formally document any major or moderate interactions between cholecalciferol and alcohol. Formal documentation for cholecalciferol does not typically note major or moderate interactions with alcohol.


Q: Are headaches a commonly reported side effect of Vidrop?

A: Headaches are a symptom that has been reported in association with general Vitamin D supplementation. This symptom is most notably observed when high levels of calcium (hypercalcemia) are present in the blood, which is the key risk associated with excessive Vitamin D intake.


Q: Does Vidrop interact with common pain relievers?

A: Official warnings exist for combination products containing cholecalciferol and certain nonsteroidal anti-inflammatory drugs (NSAIDs). The warning is due to the potential for increased gastrointestinal irritation when these agents are used together.


Q: Why is Vidrop used by many people?

A: Vidrop is a widely used medicine because it supplies cholecalciferol (Vitamin D₃), an ingredient described by health authorities as essential for overall health. It plays a critical role in the body’s ability to absorb calcium, which is necessary for skeletal health and bone maintenance.


Q: Can Vidrop be crushed or split?

A: Vidrop is an oral solution formulated as drops, not a solid tablet or capsule. Regulatory instructions state that this liquid form should be measured precisely using the provided device and may be mixed with a small amount of food or liquid for administration.


Q: What is the difference between Vidrop and other similar drugs I've heard of?

A: Vidrop contains the active ingredient cholecalciferol (Vitamin D₃). The primary difference between Vidrop and other similar medicines is typically a difference in the specific strength, formulation (such as drops vs. tablet), or the inactive ingredients used by the manufacturer. They all supply the same active ingredient, cholecalciferol (Vitamin D₃).


Q: Are there known weight changes associated with Vidrop use?

A: While not commonly reported in primary safety documents, appetite loss and weight loss have been reported in association with high blood calcium levels (hypercalcemia). Hypercalcemia is a serious side effect that can result from excessive intake of Vitamin D.


Q: Is Vidrop considered a controlled substance?

A: Vidrop's active ingredient, cholecalciferol (Vitamin D₃), is pharmacologically classified as a Vitamin D Analog. Regulatory documents indicate that it is not listed as a controlled substance in the United States.


Q: Can Vidrop affect the results of lab tests?

A: Yes, Vidrop has a direct influence on lab test results. Official regulatory documents specify that treatment requires the monitoring of serum calcium and phosphate levels, as well as the active Vitamin D metabolite, 25-hydroxyvitamin D.


Q: What kind of studies support the use of Vidrop?

A: The use of Vidrop is supported by a variety of research, including large Randomized Controlled Trials (RCTs) that study outcomes in specific disease areas. Additionally, dedicated Cardiovascular Outcomes Trials (CVOTs) have been conducted to track long-term safety related to the heart and blood vessels.


Q: How is the safety profile of Vidrop generally described in official documents?

A: The official safety profile for Vidrop is well-documented and primarily centers on its impact on the body's calcium metabolism. The most significant safety risk, which is often linked to high doses, is the potential for Hypercalcemia (excessively high blood calcium).


Q: Can Vidrop be used by teenagers?

A: Vidrop is generally established for use across all age groups for the prevention and treatment of Vitamin D deficiency. Specific high-dose formulations may carry restrictions, but low-dose Vidrop is often included in pediatric use guidelines, including for infants and adolescents.


Q: Is it true that Vidrop is used for conditions other than what is listed in the primary materials?

A: The primary authorized purpose of Vidrop is the prevention and treatment of Vitamin D deficiency. However, the active ingredient, cholecalciferol, has been examined in studies for its potential role in certain bone disorders and support for the immune system.


Q: How is Vidrop classified by drug regulatory agencies?

A: Vidrop (cholecalciferol) is formally classified by regulatory agencies as a Vitamin D Analog and, by its chemical nature, is defined as a fat-soluble vitamin.


Q: Are there any specific lifestyle changes that are often studied alongside Vidrop use?

A: Official patient management guidelines often note that optimal Vitamin D status is dependent on multiple factors, including calcium intake and sunlight exposure.


Q: What is the maximum number of times Vidrop can be taken in a day?

A: Standard usage protocols for Vidrop typically involve a once-daily administration. The daily use is defined by an established protocol to determine the appropriate amount.


Q: Do regulatory bodies publish specific guidelines for the use of Vidrop in certain patient groups?

A: Yes, regulatory bodies publish specific guidance to ensure appropriate use. For instance, detailed dose guidelines are provided for the pediatric population, and strict use restrictions are noted for patients with severe renal impairment.


Q: Is a follow-up appointment necessary after starting Vidrop?

A: Regulatory guidance notes that follow-up monitoring is often a part of patient management. For patients with certain conditions or those on long-term treatment, official product information specifies that blood calcium and 25-hydroxyvitamin D levels are typically monitored.


Q: Are there specific food groups that are mentioned as interacting with Vidrop?

A: Official information mentions that substances which interfere with fat absorption, such as mineral oil laxatives and bile acid sequestrants, can reduce the absorption of Vidrop. This is because Vidrop's active ingredient is a fat-soluble vitamin.


Q: Is the drug Vidrop used in children?

A: Yes, Vidrop is generally established for use across all age groups, including infants and children. Official guidelines contain specific dosing regimens defined for pediatric populations to address and prevent Vitamin D deficiency.


Q: Does Vidrop have any warnings related to operating machinery?

A: Official product information does not typically include explicit warnings about operating machinery. This is because the common adverse effects primarily relate to the gastrointestinal system and calcium metabolism, and do not usually impair a person's ability to drive or operate equipment.


Q: What is the typical timeframe for seeing the full benefits of Vidrop?

A: According to official information, the maximum effect on the body’s levels of the circulating Vitamin D metabolite (calcidiol) is typically observed about one month following the start of consistent daily administration.


Q: Are mood changes listed as a possible side effect of Vidrop?

A: While not a common effect, official sources indicate that irritability is a symptom that has been reported in association with high levels of calcium (hypercalcemia). This is a risk associated with excessive Vitamin D intake.

How should Vidrop be stored and disposed of?

How to Store and Dispose of Vidrop?

The official storage conditions for Vidrop (Cholecalciferol oral drops) focus on maintaining product stability and ensuring safety. The medicine must be kept at a temperature below 25 C and should not be refrigerated.

Storage Requirements

Vidrop must be stored in its original packaging to protect the contents from both moisture and light. It is a mandatory requirement that the medicine be kept out of the sight and reach of children at all times.

Disposal

Do not use the medicine past the expiry date labeled on the package. Unused, unwanted, or expired Vidrop must not be disposed of in household waste or wastewater. Instead, ask a healthcare professional or pharmacist for guidance on how to discard the product according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vidrop found in:

A-Z Index: